Joji Nakayama - Daiichi Sankyo CEO and President and Representative Director
| DSNKY Stock | USD 30.29 0.17 0.56% |
CEO
Mr. George Joji Nakayama was serving as Chairman of the Board, Chief Executive Officer and Representative Director in Daiichi Sankyo Company, Limited since April 1, 2017. His previous titles include Director of Europe Management, Director of Overseas, Managing Executive Officer, Executive Vice President, Executive President and President in the Company. He used to work for Suntory Holdings Limited and other companies. since 2017.
| Age | 67 |
| Tenure | 7 years |
| Phone | 81 3 6225 1111 |
| Web | https://www.daiichisankyo.com |
Daiichi Sankyo Management Efficiency
The company has return on total asset (ROA) of 0.0209 % which means that it generated a profit of $0.0209 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.0432 %, meaning that it generated $0.0432 on every $100 dollars invested by stockholders. Daiichi Sankyo's management efficiency ratios could be used to measure how well Daiichi Sankyo manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | CEO Age | ||
| Chris Ilsley | Novartis AG ADR | N/A | |
| Richard Saynor | Novartis AG ADR | 57 | |
| Jacob Naarden | Eli Lilly and | 39 | |
| Pascal Soriot | AstraZeneca PLC ADR | 60 | |
| William Anderson | Roche Holding Ltd | 57 | |
| Severin Schwan | Roche Holding Ltd | 56 | |
| Michael Heuer | Roche Holding Ltd | 64 | |
| Michael Ball | Novartis AG ADR | 62 | |
| Bruno Strigini | Novartis AG ADR | N/A | |
| Joseph Jimenez | Novartis AG ADR | 58 | |
| Francesco Balestrieri | Novartis AG ADR | N/A | |
| Osamu Nagayama | Roche Holding Ltd | 69 | |
| Elizabeth Barrett | Novartis AG ADR | 56 | |
| PerOlof Attinger | Roche Holding Ltd | 58 | |
| Paul Hudson | Novartis AG ADR | 51 | |
Management Performance
| Return On Equity | 0.0432 | |||
| Return On Asset | 0.0209 |
Daiichi Sankyo Leadership Team
Elected by the shareholders, the Daiichi Sankyo's board of directors comprises two types of representatives: Daiichi Sankyo inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Daiichi. The board's role is to monitor Daiichi Sankyo's management team and ensure that shareholders' interests are well served. Daiichi Sankyo's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Daiichi Sankyo's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Masahiko Ohtsuki, Executive Officer, Senior Director of Research in Main Research & Development Unit | ||
| Joji Nakayama, CEO and President and Representative Director | ||
| Sunao Manabe, Managing Executive Officer and Presidentident of Japan Company, Chief Director of Business Promotion, Director | ||
| Toshiaki Sai, Executive Officer, Director of Product Strategy in Main Strategy Unit | ||
| Tsuguya Fukui, Independent Director | ||
| Hiroshi Toda, Independent Director | ||
| Hideyuki Haruyama, Co Adviser | ||
| Hiroshi Hirabayashi, Independent Director | ||
| Sunao DVM, Group Pres | ||
| Shinichi Tobita, Executive Officer, Director of Marketing in Main Pharmaceutical Sales Unit | ||
| Toshiaki Tojo, Executive Officer, Director of Credibility Assurance | ||
| Naoyuki Kishi, Executive Officer, Chief Director of Pharmaceutical Technology | ||
| Naoki Adachi, Independent Director | ||
| Kentaro Asakura, VP Department | ||
| Shuji Handa, Managing Executive Officer and Presidentident of ASCA Company | ||
| Yoshihiro Aoyagi, VP of Legal Affairs Department, General Affairs and HR Division and Corporate Officer | ||
| Junichi Fukute, Executive Officer, Director of Supply Chain Planning in Main Supply Chain Unit | ||
| Kazuo Sato, Executive Officer, Director of License in Main Strategy Unit | ||
| Yoshikazu Fukuchi, Executive Officer, Chief Director of Medical Affairs | ||
| Manabu Sakai, Head of Corporate Management Division, Executive VP and Representative Director | ||
| Hideyuki Hirano, Executive Officer, Director of Sales Planning in Main Pharmaceutical Sales Unit | ||
| Koji Ogawa, Executive Officer and Presidentident of ASCA Company | ||
| Yuki Sato, Head of Legal Affairs and CSR Division, Head of General Affairs and HR Division, Head of Supply Chain Division, Executive VP and Representative Director | ||
| Naoto Tsukaguchi, Corp Counsel | ||
| Masayuki Yabuta, Executive Officer, Director of Biologics | ||
| Junichi Onuma, VP Department | ||
| Norimasa Kamura, Director of Human Resources, Executive Officer | ||
| Hirosumi Izawa, Executive Officer, Chief Director of Reliability Guarantee | ||
| Kunio Ishihara, Independent Director | ||
| Marielle MD, Global Devel | ||
| Glenn Gormley, Senior Managing Executive Officer, Chief Director of Research & Development | ||
| Takeshi Ogita, Senior Managing Executive Officer, Chief Director of General Affairs and Human Resources, Chief Director of Vaccine Business in Japan Company, Director | ||
| Shinichi Terano, Executive Officer, Manager of Tokyo Office in Main Medical Sales Unit of Japan Company | ||
| Takeshi Hamaura, Executive Officer, Chief Director of Pharmaceutical Technology, Director of CMC Planning | ||
| Takashi Matsumoto, Co HR | ||
| Katsumi Fujimoto, Executive Officer, Chief Director of Medicine Manufacturing Technology | ||
| Kentaro Murakawa, Executive Officer, Manager of Tokyo Office in Main Pharmaceutical Sales Unit | ||
| Yuichi Kubo, VP of Bus. Devel. andLicensing Department - Corporate Strategy Division and Corporate Officer | ||
| Ryoichi Watanabe, Director of Finance and Accounting | ||
| Noriaki Ishida, VP of Corporate Communications Department - Corporate Management Division and Executive Officer | ||
| Noritaka Uji, Independent Director | ||
| Masahiro Ohtsuki, Executive Officer, Director of Main Research Development Unit Research In Charge | ||
| Kohei Wada, Executive Officer, Director of Main Research Development Unit Development In Charge | ||
| Hiroyuki Okuzawa, Executive Officer and Presidentident of ASCA Company | ||
| Hironobu Furuta, Executive Officer, Director of Human Resources in Main General Affairs Unit | ||
| Ryoji Nagasaka, Executive Officer, Manager of Kyushu Office in Main Medical Sales of Japan Company | ||
| Satoru Kimura, Head of Sales and Marketing Division and Executive Officer | ||
| Junichi Koga, Executive Officer, Senior Director of Bio | ||
| Shoji Hirashima, Executive Officer, Director of Business Promotion in Main Business Strategy Unit | ||
| Kentaro Takamura, Director of Finance & Accounting | ||
| Kazuyuki Watanabe, Executive Officer | ||
| Akio Sakurai, Corp Unit | ||
| Yoshinori Kaneshima, Corp Unit | ||
| Kazunori Hirokawa, Senior Managing Executive Officer, Chief Director of Strategy, Chief Director of Japan Company Business Promotion, Director | ||
| Koichi Akahane, Executive Officer, Director of Research Development Planning in Main Research and Development Unit | ||
| Kenji Katsumi, Executive Officer, Director of General Affairs & Procurement in Main General Affairs Unit |
Daiichi Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Daiichi Sankyo a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.0432 | |||
| Return On Asset | 0.0209 | |||
| Profit Margin | 0.05 % | |||
| Operating Margin | 0.06 % | |||
| Current Valuation | 57.82 B | |||
| Shares Outstanding | 1.92 B | |||
| Shares Owned By Institutions | 0.21 % | |||
| Price To Earning | 92.74 X | |||
| Price To Book | 5.98 X | |||
| Price To Sales | 0.06 X |
Pair Trading with Daiichi Sankyo
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Daiichi Sankyo position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Daiichi Sankyo will appreciate offsetting losses from the drop in the long position's value.Moving together with Daiichi Pink Sheet
| 0.63 | LLY | Eli Lilly Earnings Call This Week | PairCorr |
The ability to find closely correlated positions to Daiichi Sankyo could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Daiichi Sankyo when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Daiichi Sankyo - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Daiichi Sankyo Co to buy it.
The correlation of Daiichi Sankyo is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Daiichi Sankyo moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Daiichi Sankyo moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Daiichi Sankyo can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Daiichi Sankyo Co. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in industry. You can also try the Commodity Directory module to find actively traded commodities issued by global exchanges.
Complementary Tools for Daiichi Pink Sheet analysis
When running Daiichi Sankyo's price analysis, check to measure Daiichi Sankyo's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Daiichi Sankyo is operating at the current time. Most of Daiichi Sankyo's value examination focuses on studying past and present price action to predict the probability of Daiichi Sankyo's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Daiichi Sankyo's price. Additionally, you may evaluate how the addition of Daiichi Sankyo to your portfolios can decrease your overall portfolio volatility.
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal |